24-27 November 2026Crocus Expo, Pavilion 2, Moscow
RU
Hold times, transfer delays, and repeated checks drain capacity in many facilities, sometimes consuming 40–60% of available production time. These routine inefficiencies underscore why continuous pharmaceutical manufacturing is shifting from pilot phase to active implementation. On the shop floor, operators feel the stop–start rhythm in real time: feeders empty, samples travel to the lab, investigations stall, and a restart. When materials keep moving under real-time controls, that friction eases and quality evidence builds as the line runs.
Supply resilience sits top of mind. Leaders want output they can scale up or down without rebuilding a site, and they want fewer points where a single deviation forces a wide recall. Continuous flow delivers steadier throughput, shorter lead times and clearer data trails for investigations. The economics help too. Smaller footprints, higher utilisation and tighter energy control support predictable cost models. Post-pandemic lessons about material shocks and logistics delays have only sharpened the case to redesign core steps.
A true continuous line links feeders, blenders, granulators, extruders, dryers and downstream finishing in a steady state. Performance hinges on Process Analytical Technology (PAT) with sensors for blend uniformity, moisture, bulk density and particle size. Closed-loop control then adjusts feeders or thermal profiles to keep the process in range.
Two ideas hold everything together. First, residence time distribution: knowing how long material spends in each unit lets you trace any disturbance and bound the affected product. Second, start-up and shutdown transients: well-defined sequences, purge volumes and discard rules protect the data trail. Integration with a Manufacturing Execution System (MES), Supervisory Control And Data Acquisition (SCADA) and a Laboratory Information Management System (LIMS) closes gaps between controls, batches and records.
Regulators have cleared a path. The International Council for Harmonisation guideline ICH Q13 sets shared expectations for the development, operation, and lifecycle management of continuous processes. Quality by Design (QbD) remains the mindset: define a design space, document the control strategy, and show how monitoring maintains the product within its limits. Real-time release testing (RTRT) becomes feasible when PAT models are validated and maintained under change control. Many teams find continuous lines simplify parts of Good Manufacturing Practice (GMP) by reducing hold times and manual intervention, provided documentation keeps pace with system complexity.
Most facilities transition in stages, adopting hybrid setups such as continuous feeding and blending before a conventional tablet press, or placing a continuous granulator ahead of a batch dryer to test stability under real conditions. Space, utilities and powder handling merit early study. Feeder calibration, refill strategy, powder rheology and attrition can make or break stability. Training matters as much as hardware. Operators learn to read control charts; QA gains comfort with model lifecycle files; maintenance teams adapt cleaning and verification routines to new duty cycles.
Continuous processing supports leaner inventories and fewer rejected lots. Material efficiency improves when deviations affect defined time slices rather than entire batches. Energy use can fall when thermal equipment operates at steady conditions rather than cycling. Shorter lead times help align production with demand, reducing warehouse exposure and expired stock risk. These gains carry weight with Environmental, Social and Governance (ESG) reporting and with procurement teams measuring waste and utility intensity per pack released.
Digital twins are moving from slides to practice. Teams model start-up transients, feeder variability and cleaning windows before changing a live recipe. Machine learning explores soft sensors for moisture or potency where direct probes struggle, always under a documented model-risk framework. Modular, skid-based units accelerate installation and future relocation. Interest is growing beyond solids, too, as continuous crystallisation and flow chemistry mature for active ingredients. Across pharmaceutical pharma packaging sectors, agendas now group these topics so production, QA and development can compare notes in one place.
Live comparisons help theory meet reality. A large pharma manufacturing expo lets teams time a start-up, watch a feeder refill under control and inspect how variance propagates through the line on a historian. Programme updates across Pharmtech latest news often highlight added sessions on ICH Q13, PAT modelling and modular skids. If your agenda includes packaging integration or lab alignment, plan routes that cross neighbouring zones before and after process demos. That habit prevents surprises when you connect unit operations on site.
If you build equipment, PAT, software, or integration services for continuous processing, submit a Pharmtech exhibit enquiry to present working evidence to decision-makers. We will help shape concise demonstrations, assemble a documentation pack that answers typical audit questions, and organise meetings with technical and commercial teams to evaluate transition paths. If Pharmtech Expo is on your calendar, we can also advise on stand flow, proof points and session tie-ins so conversations move from interest to defined next steps.
